Biotechnology, at the forefront of the fight against sepsis, one of the world's most serio... 13/09/2024 Sepsis is a potentially life-threatening condition that occurs when the body's immune system reacts in an extreme way to... AseBio
ORYZON receives “Intention to grant” communication for patent relating to the use of vafid... 11/09/2024 Healthcare Innovative drugs The intention to grant is a formal communication from the EPO in which it indicates that the patent application has... Partners - Oryzon Genomics
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy efectiveness by 40% in pa... 09/09/2024 Healthcare Innovative drugs Ibrilatazar is an oral drug with a novel mechanism of acton that induces autophagy through the inducton of ER-stress and... Partners - Ability Pharmaceuticals
ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadade... 09/09/2024 Healthcare Innovative drugs Exploring the triple combination with venetoclax and azacitidine. Study sponsored by Oregon Health & Science University... Partners - Oryzon Genomics
ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decis... 03/09/2024 Healthcare Rare diseases Innovative drugs In Australia, Malaysia and Mexico. Partners - Oryzon Genomics
Vaxdyn awarded €14.5 Million from the EIC Accelerator to Fund the Clinical Phase of Its Va... 02/09/2024 Healthcare Access to innovation Innovative drugs Antibiotic resistance The European Commission is committed to combating antibiotic resistance through vaccines, selecting Vaxdyn's competitive... Partners - Vaxdyn
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZ... 08/08/2024 Healthcare Innovative drugs ABTL0812 has been given the International Non-proprietary Designation (INN) ibrilatazar on the recommended list of INNs... Partners - Ability Pharmaceuticals
Peaches Biotech ready to enter into the production of biological medicines with the Histok... 06/08/2024 Healthcare Access to innovation Innovative drugs Advanced therapies The Madrid-based laboratory, together with Histocell and Cardiva, has launched Histokine, located in the Basque Country... Partners - PEACHES BIOTECH S.L.
ORYZON reports financial results and corporate update for half-year ending June 30, 2024 01/08/2024 Healthcare Access to innovation Innovative drugs Advanced therapies Research and development (R&D) expenses of $4.9m for the half-year ending June 30, 2024. As a result of the completion... Partners - Oryzon Genomics
What is Open Innovation in pharmaceutical R&D? 18/07/2024 Healthcare Access to innovation Drug discovery Innovative drugs The core idea of Open innovation is that companies leverage the ideas and resources of external actors such as customers... Partners - GENESIS Biomed
